Drug intelligence / Profile preview

LNL016

Development stage: Preclinical
Lead developer: L&L Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

LNL016 is a bispecific antibody candidate being developed by L&L Biopharma for the treatment of various solid tumors, including gastric cancer, pancreatic cancer, and non-small cell lung cancer (NSCLC). Currently in the IND-enabling (pre-IND) stage of development, the specific molecular targets of this bispecific antibody have not yet been disclosed by the company. It represents part of L&L Biopharma's pipeline of next-generation biologics aimed at addressing resistant or difficult-to-treat cancers.

Beyond the preview

Go deeper on LNL016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LNL016.

Explore the full profile